Purpose To investigate whether postoperative adjuvant trastuzumab plus chemotherapy
negatively affected cognitive functioning during the post-chemotherapy period compared …

PURPOSE We report findings on quality of life (QoL) in the RESPECT trial, which compared
adjuvant trastuzumab monotherapy with trastuzumab plus chemotherapy in older patients …

Pharmacological therapy targeting the HER2 protein is one of the major breakthroughs in
the treatment of cancer patients overexpressing HER2 who have increased survival rates …

Background: Although trastuzumab therapy improves survival in patients with human
epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, 40% of …

Objective This trial is conducted to investigate the benefit of trastuzumab monotherapy
compared with a combination therapy of trastuzumab and chemotherapy in women over 70 …

Purpose To gauge the effects of treatment practices on prognosis for older patients with
HER2-positive early breast cancer, particularly to determine whether adjuvant trastuzumab …

Purpose To evaluate the impact of chemotherapy on subjective cognitive functioning
according to age in a large cohort of breast cancer patients. Methods Within the UMBRELLA …

510 Background: The relative value of trastuzumab (H) monotherapy as an adjuvant
treatment compared to the standard combination treatment with chemotherapy (CT) is not …

Abstract Background Trastuzumab (Herceptin®; Genentech, Inc.; South San Francisco, CA)
provides clinical benefit when combined with chemotherapy or as monotherapy in patients …

Abstract Background and Objective Trastuzumab is a standard care as adjuvant
chemotherapy (AdjCT) for patients with human epidermal growth factor receptor 2 (HER2) …